ArticleBMC cancer2025
Hypoxia-driven metastatic progression in synovial sarcoma: insights from SYO-1 and SW982 models.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSynovial sarcoma (SS) is a rare but aggressive soft tissue malignancy characterized by a high rate of pulmonary metastasis and limited response to conventional therapies. Hypoxia, a common feature of tumor microenvironment, has been implicated in cancer progression, yet its specific contribution to metastatic dissemination in SS remains insufficiently characterized.
methodsWe investigated the effects of hypoxia on metastatic behavior in two SS cell lines: SYO-1 (SS18-SSX2 fusion-positive) and SW982 (fusion-negative). Cells were cultured under hypoxic (O₂ < 1%) and normoxic (21% O₂) conditions, followed by reoxygenation. Expression of hypoxia-responsive and metastasis-related genes (e.g., HIF-1α, CA9, VEGF, IGF2, ADM, YB-1, TGF-β1) was assessed via qRT-PCR. To evaluate in vivo metastatic potential, a lung colonization model was established by injecting pretreated cells into the tail veins of immunodeficient (NMRI nu/nu) mice.
resultsHypoxia significantly upregulated canonical HIF-1α targets in both cell lines, with SYO-1 showing stronger and more sustained induction, particularly of CA9 and VEGF. In vivo, SYO-1 cells formed significantly more micrometastatic lung lesions compared to SW982, with distinct perivascular clustering and signs of early intravasation. SW982 cells exhibited limited, diffuse infiltration and lower hypoxia-induced gene activation. These differences suggest that the SS18-SSX fusion may synergize with hypoxia signaling to enhance metastatic potential. Notably, HIF-1α, CA9, and IGF2 expression correlated with metastatic capacity, while TGF-β1 expression declined under hypoxia, indicating a dynamic regulation of prometastatic pathways.
conclusionOur findings demonstrate that hypoxia promotes SS metastasis through activation of HIF-1α and related pathways. Fusion-positive SS cells appear particularly responsive to hypoxic cues, suggesting that targeting hypoxia-induced signaling could be a promising strategy to inhibit metastasis in SS. These results provide mechanistic insight into SS progression and support the integration of hypoxia-targeted therapies into future treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.